Publication Topic

Visconti R, Foy J, Brennan S, Collins N, Kolaja K. An in vitro model of il-2-mediated Type 2 innate lymphoid cell proinflammatory cytokine secretion. Abstract #3377, Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019.

Wheeler MW. 2019. Bayesian additive adaptive basis tensor product models for modeling high dimensional surfaces: An application to high-throughput toxicity testing. Biometrics 75(1):193-201; doi: 10.1111/biom.12942. PMCID: PMC6363906.

Sedykh A, Choksi N, Allen D, Kleinstreuer N, Casey W, Shah R. Mixture-based modeling of chemical ocular toxicity based on the US EPA hazard categories. Poster presented at Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019

Casey WM, Chang X, Allen DG, Ceger PC, Choksi NY, Hsieh JH, et al. 2018. Evaluation and optimization of pharmacokinetic models for in vitro to in vivo extrapolation of estrogenic activity for environmental chemicals. Environ Health Perspect 126(9):97001; doi: 10.1289/EHP1655.

Covington TR, Ott DK, Gearhart JM, Pangburn HA. A physiologically-based pharmacokinetic model to address physiological changes associated with high-performance aircraft flight. Presentation at the Annual Meeting of the Military Health System Research Symposium, Orlando, FL, August 2018.

Patlewicz G, Wambaugh JF, Felter S, Simon TW, Becker RA. 2018. Utilizing Threshold of Toxicological Concern (TTC) with High Throughput Exposure Predictions (HTE) as a risk-based prioritization approach for thousands of chemicals. Comput Toxicol 7(Aug):58-67; doi: 10.1016/j.comtox.2018.07.002. PMID: 31338483.

Powles MA, Galgoci A, Misura A, Colwell L, Dingley K, Tang W, et al. 2018. In vivo efficacy of relebactam (MK-7655) in combination with imipenem/cilastatin in murine infection models. Antimicrob Agents Chemother 62:e02577–17; doi: 10.1128/AAC.02577-17. PMID: 29866878.

Fitzpatrick JM, Roberts DW, Patlewicz G. 2018. An evaluation of selected (Q)SARs/expert systems for predicting skin sensitization potential. SAR QSAR Environ Res 29(6):439-468; doi: 10.1080/1062936X.2018.1455223. PMID: 29676182.

Abramson MM, Bare JL, Barlow CA, Scott PK. 2018. Evaluation of the uncertainties associated with the use of air dispersion modeling to estimate historical community exposure from manufacturers of asbestos-containing products. Platform Presentation at Air and Waste Management Association’s (AWMA) Annual Conference and Exhibition: Conference Proceedings, Hartford, CT, June 2018.

Covington TR, Ott DK, Gearhart JM, Pangburn HA. Development of a physiologically-based pharmacokinetic model for the virtual high-performance aircraft pilot. Poster presented at Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.

Haber LT, Dourson ML, Allen BC, Hertzberg RC, Parker A, Vincent MJ, et al. 2018. Benchmark dose (BMD) modeling: Current practice, issues, and challenges. Crit Rev Toxicol 48(5):387–415; doi: 10.1080/10408444.2018.1430121.

Roberts DW, Patlewicz G. 2018. Non-animal assessment of skin sensitization hazard – Is an integrated testing strategy needed, and if so what should be integrated? J Appl Toxicol 38(1):41-50; doi: 10.1002/jat.3479. PMID: 28543848.

Bare JL, Abramson MM, Barlow CA, Scott PK. 2017. Use of air dispersion modeling to estimate historical community exposure from manufacturers of asbestos-containing products. Abstract P.96, Society for Risk Analysis (SRA) Annual Meeting, Arlington, VA, December 2017.

Liu J, Patlewicz G, Williams A, Thomas RS, Shah I. 2017. Predicting organ toxicity using in vitro bioactivity data and chemical structure. Chem Res Toxicol 30(11):2046-2059; doi: 10.1021/acs.chemrestox.7b00084. PMID: 28768096.

Wheeler MW, Bailer AJ, Cole T, Park RM, Shao K. 2017. Bayesian quantile impairment threshold benchmark dose estimation for continuous endpoints. Risk Anal 37(11):2107-18; doi: 10.1111/risa.12762. PMCID: PMC5740488.

Judson RS, Martin M, Patlewicz G, Wood CE. 2017. Retrospective mining of toxicology data to discover multispecies and chemical class effects: Anemia as a case study. Regul Toxicol Pharmacol 86(June):74-92; doi: 10.1016/j.yrtph.2017.02.015. PMID: 28242142.

Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol 325(15 June):9-17; doi: 10.1016/j.taap.2017.03.023.

Borghoff SJ, Ring C, Banton MI, Leavens TL. Ethyl tertiary butyl ether (ETBE) and tertiary butyl alcohol (TBA) physiologically based pharmacokinetic (PBPK) model in rats: Contribution of binding to 2u-globulin and non-linear kinetics to kidney and liver responses in rats. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Kirman CR, Proctor D, Suh M, Haws L, Harris M, Thompson C, Hays S. Using physiologically based pharmacokinetic modeling to address potentially sensitive subpopulations exposed to hexavalent chromium. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Covington TR, Pangburn HA, Mayes RS, Ott DK, Gearhart JM. Estimated inter-individual variations in high-performance aircraft pilot exposures using physiologically-based pharmacokinetic (PBPK) modeling and Monte Carlo analysis. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.